These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37532179)

  • 1. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
    Natarajan B; Tabrizian P; Hoteit M; Frenette C; Parikh N; Ghaziani T; Dhanasekaran R; Guy J; Shui A; Florman S; Yao FY; Mehta N
    Am J Transplant; 2023 Nov; 23(11):1771-1780. PubMed ID: 37532179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
    Huang AC; Dodge JL; Yao FY; Mehta N
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1581-1589. PubMed ID: 36038129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
    Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.
    Tan DJH; Lim WH; Yong JN; Ng CH; Muthiah MD; Tan EX; Xiao J; Lim SY; Pin Tang AS; Pan XH; Kabir T; Bonney GK; Sundar R; Syn N; Kim BK; Dan YY; Noureddin M; Loomba R; Huang DQ
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1475-1484. PubMed ID: 35181565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
    Goldman ML; Zhou K; Dodge JL; Yao F; Mehta N
    Liver Transpl; 2022 May; 28(5):763-773. PubMed ID: 34927344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis.
    Wong LL; Naugler WE; Schwartz J; Scott DL; Bhattacharya R; Reyes J; Orloff SL
    Clin Transplant; 2013; 27(1):E72-9. PubMed ID: 23278701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.